US FDA approves Granules India units

By Staff
|
Google Oneindia News

New Delhi, May 14 (UNI) Pharmaceutical company Granules India Ltd today said the US Food and Drug Administration (FDA) has approved two of its drug making units in Andhra Pradesh.

The FDA has approved company's pharmaceutical formulation intermediates unit in Gagillapur and a bulk drug unit at Bonthapally.

The Gagillapur PFI facility was re-audited by the FDA and approved, following the filing of an ANDA by one of the company's customers in the US.

The Bonthapally new API facility, manufacturing 12,000 MT of Acetaminophen/Paracetamol API was audited and approved by the FDA following a special request made by the company to schedule the inspection of this plant.

''This approval of our Acetaminophen facility by the FDA will help us get into high-value combination products of Acetaminophen at the formulations level apart from giving the comfort to our customers that Granules adopts the highest standards of Quality Management even for a product like Acetaminophen where having an FDA inspected plant is not a pre-requisite to be a supplier,'' company's Managing Director Krishna Prasad said.

The Gagillapur facility has the capacity to manufacture 7,200 MTPA of PFI and is the site for the new tableting block of the Company with a capacity of 12 billion tablets, a statement said.

UNI

For Daily Alerts
Get Instant News Updates
Enable
x
Notification Settings X
Time Settings
Done
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
X